Obesity and hepatocellular carcinoma: hype and reality.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed.

1. Targeting the hepatic circadian clock concomitant with tyrosine kinase inhibition reverses late-stage hepatocellular carcinoma.Cell reports · 2025
   Article
2. Hepatitis B infection is associated with periodontitis: the national health and nutrition examination survey (2009-2014).BMC oral health · 2024
   Article
3. Don't Judge a Book by Its Cover: The Role of Statins in Liver Cancer.Cancers · 2023
   Review
4. GST-Perfringolysin O production for the localization and quantification of membrane cholesterol in human and mouse brain and liver.STAR protocols · 2022
   Article
5. Walking and taking vitamin C alleviates oxidative stress and inflammation in overweight students, even in the short-term.Frontiers in public health · 2022
   Article
6. Ezetimibe and Cancer: Is There a Connection?Frontiers in pharmacology · 2022
   Review
7. Dietary and Genetic Cholesterol Loading Rather Than Steatosis Promotes Liver Tumorigenesis and NASH-Driven HCC.Cancers · 2021
   Article
8. Iron at the Interface of Hepatocellular Carcinoma.International journal of molecular sciences · 2021
   Review
9. Type 2 Diabetes: A Risk Factor for Hospital Readmissions and Mortality in Australian Patients With Cirrhosis.Hepatology communications · 2020
   Article
10. Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease.Frontiers in oncology · 2020
    Review
11. Epidemiology and Management of Hepatocellular Carcinoma.Gastroenterology · 2019
    Review
12. Long-Term Oncologic Outcomes Following Robotic Liver Resections for Primary Hepatobiliary Malignancies: A Multicenter Study.Annals of surgical oncology · 2018
    Article
13. Molecular Pathogenesis of Liver Cancer.Journal of gastrointestinal cancer · 2017
    Review
14. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection.Hepatology (Baltimore, Md.) · 2016
    Article
15. Sex and Ethnic Differences in the Association of Obesity With Risk of Hepatocellular Carcinoma.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2016
    Article
16. Hepatobiliary Tumors: Update on Diagnosis and Management.Journal of clinical and translational hepatology · 2015
    Review
17. Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin.World journal of hepatology · 2015
    Review
18. Adipose tissue-secreted miR-27a promotes liver cancer by targeting FOXO1 in obese individuals.OncoTargets and therapy · 2015
    Article
19. Association of Periodontal Diseases and Liver Fibrosis in Patients With HCV and/or HBV infection.Hepatitis monthly · 2014
    Article

Corrections and comments

• Comment on
  Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer.2014

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as